Unilever Looks to Offload $33 Billion Food Arm to McCormick

Unilever is in talks to sell its food business to McCormick, a unit with potential equity value up to €29bn (~$33bn). The transaction would be the largest in McCormick’s history (McCormick market cap $14.5bn vs Unilever £101bn/$135bn) and is likely to be structured as a Reverse Morris Trust; discussions aim to conclude by month-end but there is no certainty a deal will be reached. Unilever shares rose as much as 1.9% intraday (stock down ~6% over the past 12 months), and the move accelerates CEO Fernando Fernandez’s strategy to shift the group toward beauty and personal care (targeting two-thirds of turnover from those categories).

Analysis

When a global conglomerate sheds a mature packaged-food arm into the hands of a much smaller strategic buyer, the primary levers of value become financing structure, regulatory carve-outs, and shelf-space rationalization rather than simple cost synergy math. Expect acquirer-side financing to be the constraining variable: equity issuance or elevated leverage will compress near-term returns and make integration upside contingent on preserving pricing power in key condiment categories.

Retailer dynamics are a second-order but durable effect: large-format grocers can accelerate private-label penetration when supplier portfolios are in flux, pressuring branded margins by 100–300bps over 12–24 months in categories where consumers trade down. Ingredient and co-packing suppliers will see volume swings and renegotiation windows — winners will be those with scale in fresh/healthier inputs, losers those exposed to legacy, highly processed SKUs.

Regulatory scrutiny and required divestitures materially change deal economics. If regulators force category-level divestments, acquirers lose the high-margin SKUs that justify aggressive bids, converting an earnings multiple arbitrage into a strategic mismatch. Near-term (weeks–months) catalysts are financing terms and conditionality; medium-term (6–36 months) catalysts are integration execution, retail roster decisions, and any forced disposals that shrink the expected synergy pool.

Positioning should reflect asymmetric event risk: upside mainly comes from multiple expansion and rationalization savings over a multi-quarter horizon, while downside is dominated by financing failure, antitrust-mandated carve-outs, or execution slippage that removes the acquirer rationale altogether.

Key Decisions for Investors

• UL — Go long core equity (2–3% NAV) with a 6–12 month horizon to capture a simplification rerate. Target +20–30% upside from multiple expansion; hard stop -12–15% if announced separation terms collapse or management guidance weakens.
• UL/PEP — Implement a relative-value pair: long UL vs short PEP (size short = 40–60% of long notional) over 3–12 months to express a rerating of beauty/personal-care exposure versus low-growth snack & beverage exposure. Reward if UL multiple expands while PEP remains stable; risk if macro consumer staples re-rate together or PEP benefits from scale-driven margin tailwinds.
• UL options — Buy a 9–12 month call spread to lever upside while capping premium outlay (debit structure targeting ~2–3x upside-to-cost). Use strikes priced for ~15–25% move to force convexity and limit financing/announcement risk.
• BCS — Buy short-dated (1–3 month) protective puts on BCS sized to hedge ~1% NAV as insurance against a near-term credit/financing shock from large cross-border M&A activity. Payoff if credit markets widen, which would amplify downside for leveraged acquirers and banking sponsors.